Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced that it has entered into an out-licensing agreement with Ono Pharmaceutical Co., Ltd., a pharmaceutical company committed to creating innovative medicines. The exclusive license agreement is for the development and commercialization of CPI-613® (devimistat), Rafael’s first-in-class clinical lead compound, which targets cancer metabolism enzymes, as well as its other related compounds.
Under the terms of the agreement, Rafael will receive a one-time upfront payment of approximately $12.9 million USD and up to an additional approximately $150.3 million USD if certain development and commercial milestones are achieved. Rafael will also receive low-double digit royalties based on net sales of the Products in Japan, South Korea, Taiwan and ASEAN (Association of Southeast Asian Nations) countries. ONO will have exclusive rights to develop and commercialize the Products for all indications in ONO’s territory. Rafael continuously retains all exclusive rights to develop and commercialize the Products outside of ONO’s territory.
“It is a true honor to partner with ONO, which is one of the oldest pharmaceutical companies in Japan with an abundance of experience in drug discovery and development. With ONO’s extensive expertise and deep roots in the region, we hope that devimistat can help fill a major gap in oncology therapeutics in Japan and other Asian countries. It is our ongoing mission to have a meaningful impact on the lives of cancer patients around the globe, and ONO enables us to have even greater reach,”
said Sanjeev Luther, President and CEO of Rafael.
“Devimistat has shown tremendous promise in clinical trials, and partnering with ONO allows us to extend the benefits of the drug to large patient populations in Asia.ONO has demonstrated an impressive track record in drug development and commercialization in Asian countries, specifically in oncology, which makes them a natural fit as our partner,”
said Howard Jonas, Chairman of Rafael.
“We are very delighted to collaborate on devimistat with Rafael, a leader in the growing field of cancer metabolism-based therapeutics,”
said Gyo Sagara, President, Representative Director of ONO.
“Devimistat has shown promising efficacy and safety in the previous clinical trials, and we believe that devimistat will be a new treatment option to patients suffering from devastating cancers in Asian countries.”